CN102140466B - Human miR-1825 antisense nucleic acid and application thereof - Google Patents
Human miR-1825 antisense nucleic acid and application thereof Download PDFInfo
- Publication number
- CN102140466B CN102140466B CN 201010612909 CN201010612909A CN102140466B CN 102140466 B CN102140466 B CN 102140466B CN 201010612909 CN201010612909 CN 201010612909 CN 201010612909 A CN201010612909 A CN 201010612909A CN 102140466 B CN102140466 B CN 102140466B
- Authority
- CN
- China
- Prior art keywords
- mir
- antisense oligonucleotide
- modification
- sequence
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Abstract
The invention discloses antisense oligonucleotide inhibiting human microRNA-1825 from expressing and application thereof. The antisense oligonucleotide is specifically combined with human miR-1825, contains a sequence complementary with at least 13 continuous nucleotides in a 5'-UCCAGUGCCCUCCUCUCC-3' nucleotide sequence, particularly a sequence of 5'-GGAGAGGAGGGCACUGGA-3'. The antisense oligonucleotide can be ribonucleotide, deoxyribonucleotide or chimera of both, and can modify any nucleotide in a chain. The miR-1825 antisense oligonucleotide effectively inhibits miR-1825 in a human glioma cell from expressing, and inhibits the cell from growing and propagating so as to effectively treat human glioma and other miR-1825 high-expression tumors.
Description
Technical field
The invention belongs to technical field of biomedical materials and pharmaceutical field.Particularly, the present invention relates to the purposes of a kind of microRNAs (miRNA), especially relate to people microRNA-1825 (people miR-1825) antisense nucleic acid and application thereof.This antisense nucleic acid can be complementary with people miR-1825, thereby suppress the expression of people miR-1825 and play antineoplastic action.The invention still further relates to the pharmaceutical composition that contains this miRNA antisense nucleic acid.
Background technology
MiRNAs is little non-coding RNA, length is 20-25bp, normally transcribed by rna plymerase ii (Pol II), general initial product is the large pri-miRNA with cap sequence (7MGpppG) and polyadenylic acid tail (AAAAA).These pri-miRNA are processed into the pre-miRNA precursor product that 70 Nucleotide form under the effect of RNase III Drosha and its cofactor Pasha.RAN-GTP and exportin 5 are transported to this precursor molecule in the tenuigenin.Subsequently, another RNase III Dicer shears it and produces the two strands that is about 22 length of nucleotides.This two strands is directed in (miRISC) complex body very soon, wherein contains Argonaute albumen, and ripe strand miRNA is retained in this mixture.Ripe miRNA is attached to the site of the mRNA complementary with it and expresses by two kinds of machine-processed negative regulator genes that depend on the sequence complementarity, and the miRNA not exclusively complementary with said target mrna suppresses its expression in the protein translation level.Yet, also evidence suggests recently, these miRNA also might affect the stability of mRNA.Use the miRNA binding site of this mechanism usually to hold non-translational region at 3 ' of mRNA.If miRNA and target site complete complementary (perhaps almost completely complementary), the combination of these miRNA often causes the degraded of target molecule mRNA so.MiRNAs is quite conservative in spore, and animal, the miRNAs that finds in plant and the fungi etc. expresses all strict tissue specificity and timing.
At present, only have the biological function of very little a part of miRNAs to be elucidated.These miRNAs regulate Growth of Cells and tissue differentiation, and are relevant with biological growth and development.A series of studies show that: miRNAs is at Growth of Cells and apoptosis, and hemocyte breaks up, and Homeobox gene is regulated, neuronic polarity, and insulin secretion, the brain form forms, and heart occurs, and plays a significant role in the processes such as late embryogenesis growth.For example, miR-273 participates in the nervous system development process of nematode; MiR-430 participates in the brain development of zebra fish; MiR-181 control Mammals hematopoietic cell is divided into the B cell; MiR-375 regulates mammalian islet cell and grows and insulin secretion; MiR-143 works at Adipocyte Differentiation; MiR-196 has participated in the Mammals four limbs and has formed, and miR-1 is relevant with heart development.Other has the researchist to find that many neural miRNAs are subject to sequential and regulate in pallium is cultivated, and shows the mRNA translation that it may control compartmentation.
MiRNA expresses relevant with kinds cancer, and these genes may play tumor suppressor gene or oncogene effect.In B cell chronic lymphatic leukemia (CLL), find to have at first the change of miRNA expression level, in various human tumors, all detect successively subsequently the variation of miRNA expression level.Research finds, it is relevant that miRNAs and tumour form, and can bring into play the effect (such as miR-15a and miR-16-1) of tumor suppressor gene, can play again the effect (such as miR-155 and miR-17-92 bunch) of oncogene.Think at present, in tumour cell, the ripe body of some miRNA or precursor expression horizontal abnormality, and the miRNA of abnormal expression plays a role by affecting the said target mrna translation, participates in neoplastic process, and plays an important role.Be subjected to the regulation and control of let-7 family such as the Ras proto-oncogene, the BCL2 anti-apoptotic genes expression is subjected to miR-15a-miR-16-1 bunch of regulation and control, and the E2F1 transcription factor is subjected to miR-17-92 bunch of regulation and control, and the BCL6 anti-apoptotic genes expression is subjected to the regulation and control of miR-127 etc.The down-regulated expression of miRNAs also has substantial connection with tumour, and this is indicating that miRNA has the function of oncogene.For example, miR-143 and miR-145 obviously downward modulation in colorectal carcinoma.What is interesting is, the precursor molecule of its hairpin structure is similar with content in the healthy tissues in tumour, and this shows, the down-regulated expression of miRNAs may be because its course of processing is damaged.But the tumor suppressor gene function of miR-143 and miR-145 may not only be confined to colorectal carcinoma, also obviously downward modulation of its expression amount in the clones such as mammary cancer, prostate cancer, uterus carcinoma, lymphatic cancer.Another report shows, miR-21 expresses increase in glioblastoma multiforme.The expression amount of this gene in tumor tissues than high 5-100 in healthy tissues doubly.
MiRNAs is natural antisense acting factor, can regulate and control the several genes relevant with propagation with eukaryote existence.Aspect oncotherapy, the application prospect of miRNA is bright.Utilizing miRNA as aspect the treatment target spot, existing experimental data support: as in the process of gemcitabine (gemcitabine) treatment, the variation of miRNA express spectra occurs; The expression level (as making miR-21 cross expression) of regulation and control part miRNA can be promoted cholangiocarcinoma cell to the susceptibility of chemotherapeutics.By introducing and the effective miRNAs in the deactivation tumour of the synthetic antisense oligonucleotide---anti-miRNA oligonucleotide (AMOs)---of the miRNA complementation with oncogene characteristic, delay its growth.Clinically, can methylate or the antisense oligonucleotide administration of locking the modifications such as nucleic acid (LNA) makes the miRNA inactivation by 2 '-O-frequent or that continue.These modifications are so that oligonucleotide is more stable, and are lower than other treatment means toxicity.Use antagomirs (with the AMOs of cholesterol coupling), can be active at Different Organs establishment miRNA behind the injection mouse, thereby may become a kind of medicine likely.Opposite, cross and express the miRNAs that those have the tumor suppressor gene effect, such as let-7 family, also can be used for the treatment of some specific tumour.
Antisense oligonucleotide (Flanagan WM.Antisense comes of age.Cancer ﹠amp; Metastasis Reviews 1998; 17 (2): 169-76) refer to one section can with the Nucleotide of the base complementrity of its target gene.Antisense oligonucleotide can suppress the expression of corresponding gene.
People microRNA-1825 (has-miR-1825) is positioned at karyomit(e) No. 20, and precursor sequence is AGAGACUGGGGUGCUGGGCUCCCCUAGACUAGGACUCCAGUGCCCUCCUCUCC.1 ripe microRNA:hsa-miR-1825 (MIMAT0006765, sequence is UCCAGUGCCCUCCUCUCC) is arranged.At present also not about the function of microRNA-1825 and the research report of expression level.
Nearly 30 years, although the complex therapy of tumour is very general clinically, but take operation as main, to be auxiliary complex therapy improve and not obvious the survival rate of tumour patient chemicotherapy, overall survival rate was still lower in 5 years, paced up and down about 30%～55%, did not significantly improve, 5 years survival rates of middle and advanced stage patient are lower, are about 20%.And all there are limitation separately in these methods, particularly to middle and advanced stage and patients with recurrent unsatisfactory curative effect, to poorer with distant metastasis person's curative effect.Therefore, seeking safer and more effective treatment approach is the difficult problem that raising tumour patient survival rate and life quality need to be resolved hurrily.
Summary of the invention
The subject matter that the present invention will solve provides the antisense nucleic acid (inhibitor) of one group of new miR-1825, be used for efficient, low toxicity or suppress innocuously the expression of miR-1825, and then treat the disease that is caused by the miR-1825 overexpression, and comprise tumour, especially be cerebral glioma.
Another problem that the present invention will solve provides the purposes of above-mentioned antisense oligonucleotide in the medicine of the relative disease of preparation treatment mir-1825 overexpression.
The again problem that the present invention will solve provides a kind of pharmaceutical composition that comprises above-mentioned antisense nucleic acid.
The inventor has designed and synthesized a series of specificitys for the different antisense nucleic acid of the length of miR-1825 different zones by extensive and deep research, and the antisense nucleic acid that checking has inhibition in culturing cell.Studies show that growth and malignant proliferation ability that these antisense nucleic acides can inhibition tumor cell.
The present invention has designed a series of antisense nucleic acid molecules that can be incorporated into the miR-1825 different positions, in culturing cell U87/MG, the antisense nucleic acid cell growth ability that checking suppresses the miR-1825 expression specificity, the impact of multiplication capacity, antisense nucleic acid molecule length can comprise 13～25 nucleotide residues, inhibition growth of human tumor cells ability in various degree, the characteristic of multiplication capacity are all arranged, wherein the shortest antisense nucleic acid length is 13 bases, and the antisense nucleic acid of different lengths all has good growth of tumour cell and proliferation inhibition activity.Therefore, above-mentioned antisense nucleic acid all can be used to prepare the preparation of inhibition tumor cell energy for growth, multiplication capacity, wherein the tumour cell of preferred miR-1825 high expression level.Finished on this basis the present invention.
A first aspect of the present invention provides the antisense oligonucleotide of a kind of miR-1825, and described antisense oligonucleotide suppresses the expression of miR-1825 in people's cell.Usually, continuous 13～18 nucleotide sequence complementations among described antisense oligonucleotide and the 5 '-UCCAGUGCCCUCCUCUCC-3 '.In a preferred embodiment of the invention, the length of described antisense oligonucleotide is 13～18 Nucleotide.More preferably, the sequence of described antisense oligonucleotide is 5 '-GGAGAGGAGGGCACUGGA-3 '.
At present, RNA is higher than the avidity of DNA and miRNA hybridization with the hybridization avidity of miRNA in the nucleic acid hybridization, has very high pharmaceutical use.But artificial-synthetic DNA's the cost far away cost than synthetic RNA is low, also has good market potential.And can adopt the chimeric antisense nucleic acid that forms that links to each other of ribose RNA monomer and ribodesose dna single body to develop as medicine.A series of antisense nucleic acid molecules of the present invention's design had both comprised dna molecular, also comprised the RNA molecule, and two kinds of molecules all have the activity that suppresses the miR-1825 expression.
The antisense nucleic acid of the present invention's design, it is active that its sequence has specific biological, it has much relations for the complementary length of the antisense nucleic acid in the site of a certain gene complementation, length such as complementation is a little, then biologic activity can be higher, inhibition also can be more better, increasing or reducing an antisense nucleic acid that is complementary to the same gene site to several bases, equally also has biologic activity in various degree, also can reach in various degree inhibition tumor cell growth and the effect of breeding, of the present invention studies show that the shortlyest reaches 13 bases and still has the effect that miR-1825 expresses that suppresses.In the antisense nucleic acid research, various chemical modification methods are a lot, comprise one or more the combination etc. that is selected from ribose modification, base modification and the phosphoric acid backbone modification.Will be clear that any modifying method that can increase antisense nucleic acid stability and bioavailability can use, such as cholesterol modification, PEG modification, thio-modification, 2 '-methoxyl group modification etc.Described antisense oligonucleotide is modified through 2 ' methoxyl group herein.
Above-mentioned antisense nucleic acid of the present invention has the effect that suppresses the miR-1825 expression.After among the cell strain U87 that above-mentioned antisense nucleic acid is transfected into the miR-1825 high expression level, growth and malignant proliferation ability that can the establishment tumour cell.
The present invention also provides a kind of pharmaceutical composition, and it contains oligonucleotide of the present invention and pharmaceutically acceptable carrier or the vehicle of safe and effective amount.This class carrier includes but not limited to: salt solution, damping fluid, glucose, water, glycerine, ethanol and combination thereof.Pharmaceutical preparation should be complementary with administering mode.Pharmaceutical composition of the present invention can be made into the injection form, for example is prepared by ordinary method with physiological saline or the aqueous solution that contains glucose and other assistant agents.
Described " significant quantity " refers to and can produce function or amount active and that can be accepted by people and/or animal to people and/or animal.
Described " pharmaceutically acceptable " composition is applicable to people and/or animal and without excessive bad side reaction (such as toxicity, stimulation and transformation reactions), the material of rational benefit/risk ratio is arranged namely.
In a third aspect of the present invention, the purposes of antisense oligonucleotide of the present invention is provided, for the preparation of the medicine of the following disease for the treatment of: treatment human body and miR-1825 cross the relevant disease of expression, comprise tumour, are preferably cerebral glioma.
As used herein, " antisense oligonucleotide " refers to the nucleotide oligomer of antisense.Antisense oligonucleotide is by base complementrity (A-T, A-U, G-C) pairing forms three chains (anti-gene) with double-stranded DNA, or forms heteroduplex (antisense) with single stranded RNA, thus the processing and the translation that copy, transcribe or transcribe rear mRNA of blocking gene.Simultaneously, double-stranded RNA can be degraded by intracellular ribonuclease H (RNaseH), thereby more effectively blocks the expression of target gene.Because antisense nucleotide can only be combined with the target sequence of reverse complemental, has specificity high, the characteristics that side effect is little.
The length of antisense oligonucleotide of the present invention is not particularly limited, and in general, in order to reach the specificity of hybridization, antisense oligonucleotide needs the Nucleotide of at least 13 monomer compositions.Usually the length of antisense oligonucleotide is 13～35bp, and for the ripe body of miRNA, better antisense oligonucleotide length is 18～25bp.
Description of drawings
Fig. 1 has shown growth and the propagation of miR-1825 antisense oligonucleotide inhibition tumor cell U87/MG cell, the U87/MG cell behind A, B the have been transfection negative control of FAM mark; C is U87/MG cell state behind the transfection negative control (5 '-CAGUACUUUUGUGUAGUACAA-3 '); D is U87/MG cell state behind the transfection miR-1825 antisense oligonucleotide (5 '-GGAGAGGAGGGCACUGGA-3 ').
Embodiment
Antisense oligonucleotide of the present invention, continuous 13～25 nucleotide sequence complementations among its sequence and 5 '-UCCAGUGCCCUCCUCUCC-3 ', and also not complementary with the RNA sequence of other genes.In a preferred embodiment of the invention, the sequence of described antisense oligonucleotide be 5 '-GGAGAGGAGGGCACUGGA-3 '.Antisense oligonucleotide provided by the invention can be modified outcome, it contains at least two, and at least 4 usually, better at least 6, at least 8 better Nucleotide do not have the Nucleotide of the modification of toxic side effects, and described modification mode comprises 2 ' methoxy substitution, thio-modification etc.In order to increase the cellular uptake rate of antisense oligonucleotide, can also on the basis of above-mentioned modification, carry out cholesterol to antisense oligonucleotide and modify or the PEGization modification.Oligonucleotide after the above-mentioned modification can continue effectively to match with target sequence, and has in vivo the longer transformation period than common not modified Yeast Nucleic Acid or thymus nucleic acid.
The present invention has following advantage:
1, antisense oligonucleotide acts on specific target site, the site of non-specific binding seldom, specificity is high;
2, antisense oligonucleotide provided by the invention is through suitable chemically modified, has that toxicity is low, side effect is little and the characteristics such as long half time;
3, antisense oligonucleotide provided by the invention has good inhibition, and the inhibiting rate of growth of tumour cell is surpassed 75%.
Below in conjunction with embodiment and accompanying drawing the present invention is described in further detail.Yet should be appreciated that and enumerate these embodiment just for an illustration, and be not to limit the scope of the invention.
Embodiment
Embodiment 1, miR-1825 antisense oligonucleotide are that U87/MG suppresses active detection to the neuroglia cell of human oncocyte
At first, by the synthetic miR-1825 antisense oligonucleotide of Shanghai JiMa pharmacy Technology Co., Ltd, sequence is: 5 '-GGAGAGGAGGGCACUGGA-3 '.The used sequence that relates in an embodiment is synthetic by Shanghai JiMa pharmacy Technology Co., Ltd.
Cell cultures:
U87/MG cell (available from typical case's culture collection council of Chinese Academy of Sciences cell bank), 10%FBS-DMEM substratum (FBS is available from Gibco, and DMEM is available from Hyclone) is cultivated, and 37 ℃, 5%CO
2Cultivate.Collect the good U87/MG cell of growth conditions, centrifugal counting is with 2 * 10
3Every hole is laid in 96 orifice plates, and 37 ℃, 5%CO
2Cultivate 24h.
Transfection:
1) transfection the day before yesterday, with not containing in right amount antibiotic culture medium inoculated culturing cell, the degree of converging of cell reaches 30～50% when making transfection in 96 orifice plates;
2) the transfection sample is prepared oligomer-Lipofecta mine as follows
TM2000 mixtures:
A. the Opti-MEM that does not contain serum with 25 μ l
I substratum (Gibco) dilutes respectively the negative control of miR-1825 antisense oligonucleotide (5 '-GGAGAGGAGGGCACUGGA-3 '), negative control (5 '-CAGUACUUUUGUGUAGUACAA-3 '), FAM mark, final concentration is 50nM after adding in the hand-hole, mixing gently, each transfection are established 3 multiple holes;
B. mixing Lipofecta mine gently before using
TM2000 (Invitrogen) then get the Opti-MEM that 0.25 μ l is diluted to 25 μ l
The I substratum is at room temperature hatched 5min gently behind the mixing;
C. after hatching 5min, the Lipofecta mine of dilution
TM2000 mix with antisense nucleotide and the contrast of dilution respectively, at room temperature hatch gently 20min behind the mixing, to allow complex formation;
3) mixture is joined in each hole that comprises cell and substratum, the culture plate that rocks back and forth lightly mixes; The final concentration of antisense nucleotide and contrast is 75nM.
4) 37 ℃, 5%CO
2After incubator continued to hatch 72 hours, microscopic examination U87/MG cell was taken a picture.
As shown in Figure 1, transfection is after 72 hours, surpassed 80% U87/MG cell success transfection the negative control of FAM mark (figure A, B); Behind the transfection negative control, the U87/MG cell is complete, light transmission strong (figure C); Most of U87/MG necrocytosis behind the transfection miR-1825 antisense oligonucleotide (figure D).
Cytotoxicity experiment based on MTT:
The cell that obtains in the previous step adds MTT (Sigma) 5mg/ml (physiological saline with 0.9% is prepared) for preparing, and every hole adds 20 μ l, 37 ℃, 5%CO
2Hatch after 4 hours and suck substratum and MTT, every hole adds DMSO 100 μ l and reads the absorbance of OD570-OD630 by microplate reader.
Calculate inhibiting rate:
The inhibiting rate that calculates Growth of Cells is 76.23 ± 2.14%.
The result shows: miR-1825 antisense oligonucleotide provided by the invention has good inhibition, and the inhibiting rate that U87/MG is grown surpasses 75%.
Claims (6)
1. an antisense oligonucleotide is for the preparation of the purposes of the medicine for the treatment of cerebral glioma, wherein, described antisense oligonucleotide sequence is the chimeric sequence with ribonucleoside acid sequence, deoxyribonucleotide sequence or ribonucleotide and the deoxyribonucleotide of the complementation of 5 '-UCCAGUGCCCUCCUCUCC-3 ' nucleotide sequence.
2. purposes as claimed in claim 1 is characterized in that, described antisense oligonucleotide sequence is 5 '-GGAGAGGAGGGCACUGGA-3 '.
3. purposes as claimed in claim 1 or 2 is characterized in that, described antisense oligonucleotide is further modified.
4. purposes as claimed in claim 3 is characterized in that, described modification is selected from one or more the combination in ribose modification, base modification and the phosphoric acid backbone modification.
5. purposes as claimed in claim 4 is characterized in that, described modification is selected from one or more in thio-modification, 2 '-methoxyl group modification and the cholesterol modification.
6. purposes as claimed in claim 1 is characterized in that, described antisense oligonucleotide and other treatment are medication combined to be used.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010612909 CN102140466B (en) | 2010-12-30 | 2010-12-30 | Human miR-1825 antisense nucleic acid and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010612909 CN102140466B (en) | 2010-12-30 | 2010-12-30 | Human miR-1825 antisense nucleic acid and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102140466A CN102140466A (en) | 2011-08-03 |
| CN102140466B true CN102140466B (en) | 2013-03-27 |
Family
ID=44408263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010612909 Active CN102140466B (en) | 2010-12-30 | 2010-12-30 | Human miR-1825 antisense nucleic acid and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102140466B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101091798A (en) * | 2007-04-17 | 2007-12-26 | 华东师范大学 | Application of meaning inversed miRNA-210 |
| CN101389770A (en) * | 2006-01-05 | 2009-03-18 | 俄亥俄州立大学研究基金会 | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of solid cancers |
| CN101400361A (en) * | 2006-01-05 | 2009-04-01 | 俄亥俄州立大学研究基金会 | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer |
| WO2009149182A1 (en) * | 2008-06-04 | 2009-12-10 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression through endogenous small rna targeting of gene promoters |
-
2010
- 2010-12-30 CN CN 201010612909 patent/CN102140466B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101389770A (en) * | 2006-01-05 | 2009-03-18 | 俄亥俄州立大学研究基金会 | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of solid cancers |
| CN101400361A (en) * | 2006-01-05 | 2009-04-01 | 俄亥俄州立大学研究基金会 | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer |
| CN101091798A (en) * | 2007-04-17 | 2007-12-26 | 华东师范大学 | Application of meaning inversed miRNA-210 |
| WO2009149182A1 (en) * | 2008-06-04 | 2009-12-10 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression through endogenous small rna targeting of gene promoters |
Non-Patent Citations (3)
| Title |
|---|
| F Lerebours 等.MicroRNA Expression Profiling of Inflammatory Breast Cancer.《Cancer Research》.2009,第69卷(第24期),6118页. * |
| Marc R Friedländer 等.Discovering microRNAs from deep sequencing data using miRDeep.《nature biotechnology》.2008,第26卷(第4期),第407-415页. * |
| 易伟峰.Micro RNA 在胶质瘤组织表达差异谱的研究.《中国现代医学杂志》.2009,第19卷(第8期),第1152-1155页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102140466A (en) | 2011-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102080086B (en) | Human miR-133a antisense nucleic acid and application thereof | |
| CN102140468A (en) | Human miR-185* antisense nucleic acid and application thereof | |
| CN102533755A (en) | Human miR-328 antisense nucleic acid and application thereof | |
| CN102382824A (en) | Human miR-145 antisense nucleic acid and application thereof | |
| CN102031256B (en) | Human miR-485-5p antisense nucleic acid and application thereof | |
| CN102140469B (en) | Human miR (microRNA)-1233 antisensenucleic acid and application thereof | |
| CN102080085B (en) | Human miR-193b antisense nucleotide and application thereof | |
| CN101993877A (en) | Human miR-296-5p antisense nucleic acid and application thereof | |
| CN102080083B (en) | Human miR-149 antisense nucleotide and application thereof | |
| CN102643811B (en) | The antisense oligonucleotide of people miR-1229 and application thereof | |
| CN102140465B (en) | Human miR-1249 antisense nucleic acid and application thereof | |
| CN102140470B (en) | Human miR-1236 antisense ribonucleic acid and application thereof | |
| CN102140467B (en) | Human miR-365 antisense nucleic acid and application thereof | |
| CN102140464B (en) | Human miR-1238 antisense nucleic acid and applications thereof | |
| CN102643807B (en) | Antisense oligodeoxyncleotide of human miR-484 and application thereof | |
| CN102643813B (en) | The antisense oligonucleotide of people miR-504 and application thereof | |
| CN102382825B (en) | Human miR-1826 antisense nucleic acid and application thereof | |
| CN102643809B (en) | The antisense oligonucleotide of people miR-1274b and application thereof | |
| CN102140462B (en) | Human miR-1260 antisense nucleic acid and application thereof | |
| CN102643810B (en) | The antisense oligonucleotide of people miR-299-5p and application thereof | |
| CN102140466B (en) | Human miR-1825 antisense nucleic acid and application thereof | |
| CN102031254A (en) | Human miR-150 antisense nucleic acid and application thereof | |
| CN102031255B (en) | Antisense nucleic acid of human miR-223 and applications of antisense nucleic acid | |
| CN102643814B (en) | Antisense oligonucleotide for human miR-431 and application thereof | |
| CN102382823B (en) | Human miR-515-5p antisense oligod-eoxynucleotide and applications thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DD01 | Delivery of document by public notice |
Addressee: Cheng Wenhong Document name: Notification that Application Deemed not to be Proposed |
|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |